Anti cancer effects of curcumin: cycle of life and death

McMichael AJ, McCall MG, Hartchorne JM, Woodings TL: Patterns of gastrointestinal cancer in European migrants to Australia: the role of dietary change. Int J Cancer 1980, 5: 431–437. 10.1002/ijc.2910250402 Wargovich MJ: Nutrition and cancer: the herbal revolution. Curr Opin Clin Nutr Metab Care 1999, 2: 421–424. 10.1097/00075197-199909000-00011 Campbell FC, Collett PG: Chemopreventive properties of curcumin. Future Oncol 2005, 1: 405–414. 10.1517/14796694.1.3.405 Sharma RA, Gescher AJ, Steward WP: Curcumin: the story so far. Eur J Cancer 2005, 41: 1955–1968. 10.1016/j.ejca.2005.05.009 Sharma OP: Antioxidant activity of curcumin and related compounds. Biochem Pharmacol 1976, 25: 1811–1812. 10.1016/0006-2952(76)90421-4 Choudhuri T, Pal S, Das T, Sa G: Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem 2005, 280: 20059–20068. 10.1074/jbc.M410670200 Bhattacharyya S, Mandal D, Sen GS, Pal S, Banerjee S, Lahiry L, Finke JH, Tannenbaum CS, Das T, Sa G: Tumor-induced oxidative stress perturbs NFκB activity augmenting TNFα-mediated T cell death: Protection by curcumin. Cancer Res 2007, 60: 362–370. 10.1158/0008-5472.CAN-06-2583 Lowe SW, Cepero E, Evan G: Intrinsic tumor suppression. Nature 2004, 432: 307–315. 10.1038/nature03098 Evan GI, Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature 2001, 411: 342–348. 10.1038/35077213 Sherr CJ: Cancer cell cycles. Science 1996, 274: 1672–1677. 10.1126/science.274.5293.1672 Danial NN, Korsmeyer SJ: Cell death: critical control points. Cell 2004, 116: 205–219. 10.1016/S0092-8674(04)00046-7 Hahn WC, Weinberg RA: Rules for making human tumor cells. N Engl J Med 2002, 347: 1593–1603. 10.1056/NEJMra021902 Norbury C, Nurse P: Animal cell cycles and their control. Annu Rev Biochem 1992, 61: 441–470. 10.1146/annurev.bi.61.070192.002301 Nurse P, Masui Y, Hartwell L: Understanding the cell cycle. Nat Med 1998, 4: 1103–1106. 10.1038/2594 Hartwell LH, Kastan MB: Cell cycle control and cancer. Science 1994, 266: 1821–1828. 10.1126/science.7997877 Diehl JA: Cycling to cancer with cyclin D1. Cancer Biol Thera 2002, 1: 226–231. Yu Q, Geng Y, Sicinski P: Specific protection against breast cancers by cyclin D1 ablation. Nature 2001, 411: 1017–1021. 10.1038/35082500 Weinstein IB: Relevance of cyclin D1 and other molecular markers to cancer chemoprevention. J Cell Biochem Suppl 1996, 25: 23–28. Publisher Full Text 10.1002/(SICI)1097-4644(1996)25+<23::AID-JCB3>3.0.CO;2-4 Hosokawa Y, Arnold A: Mechanism of cyclin D1 (CCND1, PRAD1) over-expression in human cancer cells: analysis of allele-specific expression. Genes Chromosomes Cancer 1998, 22: 66–71. 10.1002/(SICI)1098-2264(199805)22:1<66::AID-GCC9>3.0.CO;2-5 Hinds PW, Dowdy SF, Eaton EN, Arnold A, Weinberg RA: Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci, USA 1994, 91: 709–713. 10.1073/pnas.91.2.709 AI Robles, ML Rodriguez-Puebla, AB Glick, C Trempus, L Hansen, P Sicinski, RW Tennant, RA Weinberg, SH Yuspa, CJ Conti: Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo . Genes Dev 1998, 12: 2469–2474. 10.1101/gad.12.16.2469 Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994, 369: 669–671. 10.1038/369669a0 Bortner DM, Rosenberg MP: Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol 1997, 17: 453–459. Harbour JW, Dean DC: Rb function in cell cycle regulation and apoptosis. Nat Cell Biol 2000, 2: 65–67. 10.1038/35008695 Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13: 1501–1512. 10.1101/gad.13.12.1501 Sa G, Stacey DW: P27 expression is regulated by separate signaling pathways, downstream of Ras, in each cell cycle phase. Exp Cell Res 2004, 300: 427–439. 10.1016/j.yexcr.2004.07.032 Ortega S, Malumbres M, Barbacid M: Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002, 1602: 73–87. Vidal A, Koff A: Cell-cycle inhibitors: three families united by a common cause. Gene 2000, 247: 1–15. 10.1016/S0378-1119(00)00092-5 Elledge SJ: Cell cycle checkpoints: preventing an identity crisis. Science 1996, 274: 1664–1672. 10.1126/science.274.5293.1664 Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991, 253: 49–53. 10.1126/science.1905840 Polyak K, Waldman T, He T-C, Kinzler KW, Vogelstein B: Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 1996, 10: 1945–1952. 10.1101/gad.10.15.1945 Levin AJ: p53, the cellular gatekeeper for growth and division. Cell 1997, 88: 323–331. 10.1016/S0092-8674(00)81871-1 Grimmler M, Wang Y, Mund T, Cilensek Z, Keidel EM, Waddell MB, Jäkel H, Kullmann M, Kriwacki RW, Hengst L: Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell 2007, 128: 269–80. 10.1016/j.cell.2006.11.047 Chu I, Sun J, Arnaout A, Kahn H, Hanna W, Narod S, Sun P, Tan CK, Hengst L, Slingerland J: p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell 2007, 128: 281–94. 10.1016/j.cell.2006.11.049 Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995, 80: 293–299. 10.1016/0092-8674(95)90513-8 Das T, Sa G, Sinha P, Ray PK: Induction of cell proliferation and apoptosis: dependence on the dose of the inducer. Biochem Biophys Res Commun 1999, 260: 105–110. 10.1006/bbrc.1999.0712 Harrington EA, Fanidi A, Evan GI: Oncogenes and cell death. Curr Opinion Genet Dev 1994, 4: 120–129. 10.1016/0959-437X(94)90100-7 Liu X, Kim CN, Yang J, Jemmerson R, Wang X: Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996, 86: 147–157. 10.1016/S0092-8674(00)80085-9 Waldman T, Yongyang Y, Diollehay L, Yu J, Kinzler KW, Vogelstein B, Williams J: Cell cycle arrest versus cell death in cancer therapy. Nat Med 1997, 3: 1034–1036. 10.1038/nm0997-1034 Strimpakos AS, Sharma RA: Curcumin: Preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 2008, 10: 511–45. 10.1089/ars.2007.1769 Oyama Y, Masuda T, Nakata M, Chikahisa L, Yamazaki Y, Miura K, Okagawa M: Protective actions of 5'-n-alkylated curcumins on living cells suffering from oxidative stress. Eur J Pharmacol 1998, 360: 65–71. 10.1016/S0014-2999(98)00635-9 Pal S, Bhattacharya S, Choudhuri T, Datta GK, Das T, Sa G: Amelioration of immune cell number depletion and potentiation of depressed detoxification system of tumor-bearing mice by curcumin. Cancer Detection Prevention 2005, 29: 470–478. 10.1016/j.cdp.2005.05.003 Sugimoto K, Hanai H, Tozawa K, Aoshi T, Uchijima M, Nagata T, Koide Y: Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 2002, 123: 1912–1922. 10.1053/gast.2002.37050 Pal S, Choudhuri T, Chattopadhyay S, Bhattacharya A, Datta G, Das T, Sa G: Mechanisms of curcumin-induced apoptosis of Ehrlich's ascites carcinoma cells. Biochem Biophys Res Commun 2001, 288: 658–665. 10.1006/bbrc.2001.5823 Ammon HP, Wahl MA: Pharmacology of Curcuma longa . Planta Med 1991, 57: 1–7. 10.1055/s-2006-960004 Vial T, Descotes J: Immunosuppressive drugs and cancer. Toxicology 2003, 185: 229–240. 10.1016/S0300-483X(02)00612-1 Choudhuri T, Pal S, Agwarwal ML, Das T, Sa G: Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. FEBS Lett 2002, 512: 334–340. 10.1016/S0014-5793(02)02292-5 Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008, 14: 4491–4499. 10.1158/1078-0432.CCR-08-0024 Aggarwal BB, Kumar A, Bharti AC: Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003, 23: 363–398. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001, 21: 2895–2900. Kuttan R, Sudheeran PC, Josph CD: Turmeric and curcumin as topical agents in cancer therapy. Tumori 1987, 73: 29–31. Garcea G, Berry DP, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, Gescher AJ: Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 2005, 14: 120–125. Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, Luo JL, Howells L, Plummer S, Jukes R, Williams M, Steward WP, Gescher A: Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E 2 production. Cancer Res 2001, 61: 1058–1064. Huang MT, Wang ZY, Georgiadis CA, Laskin JD, Conney AH: Inhibitory effects of curcumin on tumor initiation by benzo[α]pyrene and 7,12-dimethylbenz[α]anthracene. Carcinogenesis 1992, 13: 2183–2186. 10.1093/carcin/13.11.2183 Huang MT, Newmark HL, Frenkel KJ: Inhibitory effects of curcumin on tumorigenesis in mice. Biochem Suppl 1997, 27: 326–34. Jee SH, Shen SC, Tseng CR, Chiu HC, Kuo ML: Curcumin induces a p53-dependent apoptosis in human basal cell carcinoma cells. J Invest Dermatol 1998, 111: 656–661. 10.1046/j.1523-1747.1998.00352.x Moos PJ, Edes K, Mullally JE, Fitzpatrick FA: Curcumin impairs tumor suppressor p53 function in colon cancer cells. Carcinogenesis 2004, 25: 1611–1617. 10.1093/carcin/bgh163 Park C, Kim GY, Kim GD, Choi BT, Park YM, Choi YH: Induction of G2/M arrest and inhibition of cyclooxygenase-2 activity by curcumin in human bladder cancer T24 cells. Oncol Rep 2006, 15: 1225–1231. Liontas A, Yeger H: Curcumin and resveratrol induce apoptosis and nuclear translocation and activation of p53 in human neuroblastoma. Anticancer Res 2004, 24: 987–998. Pillai GR, Srivastava AS, Hassanein TI, Chauhan DP, Carrier E: Induction of apoptosis in human lung cancer cells by curcumin. Cancer Lett 2004, 208: 163–170. 10.1016/j.canlet.2004.01.008 Shi M, Cai Q, Yao L, Mao Y, Ming Y, Ouyang G: Antiproliferation and apoptosis induced by curcumin in human ovarian cancer cells. Cell Biol Int 2006, 30: 221–226. 10.1016/j.cellbi.2005.10.024 Jaiswal AS, Marlow BP, Gupta N, Narayan S: Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 2002, 21: 8414–8427. 10.1038/sj.onc.1205947 Bharti AC, Donato N, Singh S, Aggarwal BB: Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003, 101: 1053–1062. 10.1182/blood-2002-05-1320 Chen A, Xu J: Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. Am J Physiol Gastrointest Liver Physiol 2005, 288: G447–456. 10.1152/ajpgi.00209.2004 Leu TH, Su SL, Chuang YC, Maa MC: Direct inhibitory effect of curcumin on Src and focal adhesion kinase activity. Biochem Pharmacol 2003, 66: 2323–2331. 10.1016/j.bcp.2003.08.017 Nakamura K, Yasunaga Y, Segawa T, Ko D, Moul JW, Srivastava S, Rhim JS: Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines. Int J Oncol 2002, 21: 825–830. Balasubramanyam K, Varier RA, Altaf M, Swaminathan V, Siddappa NB, Ranga U, Kundu TK: Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 2004, 279: 51163–51171. 10.1074/jbc.M409024200 Collett GP, Campbell FC: Curcumin induces c-jun N-terminal kinase-dependent apoptosis in HCT116 human colon cancer cells. Carcinogenesis 2004, 25: 2183–2189. 10.1093/carcin/bgh233 Deeb D, Xu YX, Jiang H, Gao X, Janakiraman N, Chapman RA, Gautam SC: Curcumin (Diferuloyl-Methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol Cancer Ther 2003, 2: 95–103. Dorai T, Gehani N, Katz A: Therapeutic potential of curcumin in human prostate cancer-I. Curcumin induces apoptosis in both androgen-dependent and androgen-independent prostate cancer cells. Prostate Cancer Prostatic Dis 2000, 3: 84–93. 10.1038/sj.pcan.4500399 Ramachandran C, Fonseca HB, Jhabvala P, Escalon EA, Melnick SJ: Curcumin inhibits telomerase activity through human telomerase reverse transcritpase in MCF-7 breast cancer cell line. Cancer Lett 2002, 184: 1–6. 10.1016/S0304-3835(02)00192-1 Wolanin K, Magalska A, Mosieniak G, Klinger R, McKenna S, Vejda S, Sikora E, Piwocka K: Curcumin affects components of the chromosomal passenger complex and induces mitotic catastrophe in apoptosis-resistant Bcr-Abl-expressing cells. Mol Cancer Res 2006, 4: 457–469. 10.1158/1541-7786.MCR-05-0172 Zheng M, Ekmekcioglu S, Walch ET, Tang CH, Grimm EA: Inhibition of nuclear factor-kappaB and nitric oxide by curcumin induces G2/M cell cycle arrest and apoptosis in human melanoma cells. Melanoma Res 2004, 14: 165–171. 10.1097/01.cmr.0000129374.76399.19 Shishodia S, Amin HM, Lai R, Aggarwal BB: Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 2005, 70: 700–701. 10.1016/j.bcp.2005.04.043 Rajasingh J, Raikwar HP, Muthia G, Johnson C, Bright JJ: Curcumin induces growth-arrest and apoptosis in association with the inhibition of constitutively active JAK-STAT pathway in T cell leukemia. Biochem Biophys Res Commun 2006, 340: 359–368. 10.1016/j.bbrc.2005.12.014 Tomita M, Kawakami H, Uchihara JN: Curcumin (diferuloylmethane) inhibits constitutive active NF-kappaB, leading to suppression of cell growth of human T-cell leukemia virus type I-infected T-cell lines and primary adult T-cell leukemia cells. Int J Cancer 2006, 118: 765–772. 10.1002/ijc.21389 Holy JM: Curcumin disrupts mitotic spindle structure and induces micronucleation in MCF-7breast cancer cells. Mutat Res 2002, 518: 71–84. Woo JH, Kim YH, Choi YJ, Kim DG, Lee KS, Bae JH, Min DS, Chang JS, Jeong YJ, Lee YH, Park JW, Kwon TK: Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis 2003, 24: 1199–1208. 10.1093/carcin/bgg082 Sa G, Hitomi M, Harwalkar J, Stacey A, Chen G, Stacey DW: Ras is active throughout the cell cycle, but is able to induce cyclin D1 only during G2 phase. Cell Cycle 2002, 1: 50–58. Sa G, Guo Y, Stacey DW: Regulation of S phase initiation by p27Kip1 in NIH3T3 cells. Cell Cycle 2005, 4: 618–627. Hitomi M, Stacey DW: Cellular ras and cyclin D1 are required during different cell cycle periods in cycling NIH 3T3 cells. Mol Cell Biol 1999, 19: 4623–4632. Mukhopadhyay A, Banerjee S, Stafford LJ, Xia CX, Liu M, Aggarwal BB: Curcumin induced suppression of cell proliferation correlates with downregulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene 2002, 21: 8852–8862. 10.1038/sj.onc.1206048 Park MJ, Kim EH, Park IC, Lee HC, Woo SH, Lee JY, Hong YJ, Rhee CH, Choi SH, Shim BS, Lee SH, Hong SI: Curcumin inhibits cell cycle progression of immortalized human umbilical vein endothelial (ECV304) cells by up-regulating cyclin-dependent kinase inhibitor, p21WAF1/CIP1, p27KIP1 and p53. Int J Oncol 2002, 21: 379–383. Bech-Otschir D, Kraft R, Huang X: COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J 2001, 20: 1630–1639. 10.1093/emboj/20.7.1630 Song G, Mao YB, Cai QF, Yao LM, Ouyang GL, Bao SD: Curcumin induces human HT-29 colon adenocarcinoma cell apoptosis by activating p53 and regulating apoptosis-related protein expression. Braz J Med Biol Res 2005, 38: 1791–1798. 10.1590/S0100-879X2005001200007 Kamath R, Jiang Z, Sun G, Yalowich JC, Rajasekaran B: c-Abl kinase regulates curcumin-induced cell death through activation of c-Jun N-terminal kinase. Mol Pharmacol 2007, 71: 61–72. 10.1124/mol.106.026575 Bush JA, Cheung KJ Jr, Li G: Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. Exp Cell Res 2001, 271: 305–314. 10.1006/excr.2001.5381 Mullally JE, Fitzpatrick FA: Pharmacophore model for novel inhibitors of ubiquitin isopeptidases that induce p53-independent cell death. Mol Pharmacol 2002, 69: 351–358. 10.1124/mol.62.2.351 Chen J, Huang CY, Guan JY, Lu SH, Pu YS: Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21WAF1/CIP1 and C/EBPβ expressions and suppressing NF-κB activation hour. The prostate 2002, 51: 211–218. 10.1002/pros.10089 Lin JK: Suppression of protein kinase C and nuclear oncogene expression as possible action mechanisms of cancer chemoprevention by curcumin. Arch Pharm Res 2004, 27: 683–692. Choi H, Chun YS, Kim SW, Kim MS, Park JW: Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition. Mol Pharmaco 2006, 70: 1664–1671. 10.1124/mol.106.025817 Mohan R, Sivak J, Ashton P, Russo LA, Pham BQ, Kasahara N, Raizman MB, Fini ME: Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B. J Biol Chem 2000, 275: 10405–10412. 10.1074/jbc.275.14.10405 Lala PK, Chakraborty C: Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2001, 2: 149–56. 10.1016/S1470-2045(00)00256-4 Bae MK, Kim SH, Jeong JW, Lee YM, Kim HS, Kim SR, Yun I, Bae SK, Kim KW: Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1. Oncol Rep 2006, 15: 1557–1562. Park CH, Hahm ER, Park S, Kim HK, Yang CH: The inhibitory mechanism of curcumin and its derivative against beta-catenin/Tcf signaling. FEBS Lett 2005, 579: 2965–2971. 10.1016/j.febslet.2005.04.013 Khopde M, Priyadarsini KI, Venkatesan P, Rao MN: Free radical scavenging ability and antioxidant efficiency of curcumin and its substituted analogue. Biophys Chem 1999, 80: 85–91. 10.1016/S0301-4622(99)00070-8 Graziewicz M, Wink DA, Laval F: Nitric oxide inhibits DNA ligase activity: potential mechanisms for NO-mediated DNA damage. Carcinogenesis 1996, 17: 2501–2505. 10.1093/carcin/17.11.2501 Mori Y, Tatematsu K, Koide A, Sugie S, Tanaka T, Mori H: Modification by curcumin of mutagenic activation of carcinogenic N-nitrosamines by extrahepatic cytochromes P-450 2B1 and 2E1 in rats. Cancer Sci 2006, 97: 896–904. 10.1111/j.1349-7006.2006.00261.x Jagetia GC, Aggarwal BB: "Spicing up" of the immune system by curcumin. J Clin Immunol 2007, 27: 19–35. 10.1007/s10875-006-9066-7 Bhaumik S, Jyothi MD, Khar A: Differential modulation of nitric oxide production by curcumin in host macrophages and NK cells. FEBS Lett 2000, 483: 78–82. 10.1016/S0014-5793(00)02089-5 Bhattacharyya S, Mandal D, Saha B, Sen GS, Das T, Sa G: Curcumin prevents tumor-induced T cell apoptosis through Stat-5a-mediated Bcl-2 induction. J Biol Chem 2007, 282: 15954–15964. 10.1074/jbc.M608189200